FACULTY
Peter A. Lio, MD Clinical Assistant Professor Dermatology and Pediatrics Northwestern University Feinberg School of Medicine Medical Dermatology Associates of Chicago Chicago, IL |
Geoffrey C. Wall, PharmD, FCCP, BCPS Professor of Clinical Sciences Drake University College of Pharmacy and Health Sciences Internal Medicine Clinical Pharmacist Iowa Methodist Medical Center |
PROGRAM OVERVIEW
This case-based activity will cover the underlying causes of atopic dermatitis along with current and emerging systemic agents as part of the overall treatment plan.
TARGET AUDIENCE
This activity is intended for managed care pharmacists, physicians, and other healthcare professionals involved in the management of patients with moderate-to-severe atopic dermatitis.
LEARNING OBJECTIVES
- Recognize patient-specific factors that influence the selection of therapies for the management of moderate-to-severe atopic dermatitis, including comorbidities, adherence barriers, disease severity, and quality-of-life issues
- Evaluate clinical trial data on the efficacy and safety of systemic and topical treatments for the management of moderate-to-severe atopic dermatitis
- Identify strategies to manage healthcare costs while improving quality of life for patients with atopic dermatitis
- Develop treatment plans that apply evidence-based medication use strategies to enhance outcomes in patients with moderate-to-severe atopic dermatitis
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with atopic dermatitis.
CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
CONTINUING PHARMACY EDUCATION CREDIT
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.00 knowledge-based CPE contact hours.
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
DISCLOSURE OF CONFLICTS OF INTEREST
Peter Lio, MD has served on the advisory board for the National Eczema Association, Modernizing Medicine, Johnson & Johnson, DermTap Inc., IntraDerm Pharmaceuticals, Regeneron, Sanofi US Services, Realm Therapeutics, Menlo Therapeutics, Syncere Skin Systems, Dermveda, GPower Inc., UCB, Altus Labs, Dermavant Sciences, Micreos Human Health B.V., Verrica Pharmaceuticals Inc., Arbonne, Yobee Care Inc., and Bodewell. Dr. Lio is a stockholder in Modernizing Medicine, LearnHealth/LearnSkin, and Medable. He has been a speaker for Pierre Fabre Dermatologie, Regeneron, Pfizer, and La Roche-Posay. He has been an investigator for La Fondation pour la Dermatite Atopique (Foundation for Atopic Dermatitis), AOBiome LLC, Regeneron, AbbVie, and National Eczema Association. He has been a consultant for Exeltis, Theraplex, Odeza LLC, L’Oréal USA Inc., Franklin BioScience, AbbVie, Kiniksa Pharmaceuticals, Eli Lilly and Co., Unilever, Dermira, TopMD, Amyris Inc., Leo Pharma, and Burt’s Bees.
Geoff Wall, PharmD has nothing to disclose.
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group has nothing to disclose.
Chris Drury, MA, MS, MBA, Director of Medical and Scientific Services, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures;
- Participate in the activity; and
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: May 7, 2021
EXPIRATION DATE: May 7, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group at [email protected].
Enduring Learner Notification
Med Learning Group
Using Managed Care to Minimize the Burden of Moderate-to-Severe Atopic Dermatitis in Pediatric and Adult Patients – Enduring
Date of CE Release: May 7, 2021
Date of CE Expiration: May 7, 2022
Online
Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.
UAN(s): JA4008163-9999-21-078-H04-P / JA4008163-9999-21-078-H04-T
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
Objectives – After Attending This Program You Should Be Able To
- Recognize patient-specific factors that influence the selection of therapies for the management of moderate-to-severe atopic dermatitis, including comorbidities, adherence barriers, disease severity, and quality of life issues.
- Evaluate clinical trial data on the efficacy and safety of systemic and topical treatments for the management of moderate-to-severe atopic dermatitis.
- Identify strategies to manage health care costs while improving quality of life for patients with atopic dermatitis.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5).
All individuals in a position to control the content of CE are listed below:
Name | Relationship: Commercial Interest |
---|---|
Chris Drury | NA |
Matthew Frese | NA |
Christina Gallo | NA |
Brianna Hanson | NA |
Peter Lio | Advisory Board: Altus Labs, Arbonne, Derma Tap, Inc., Dermavant Sciences, Dermveda, GPower Inc., IntraDerm Pharmaceuticals, Johnson & Johnson, Menlo Therapeutics, Micreos Human Health B.V., Modernizing Medicine, Realm Therapeutics, Regeneron, Sanofi, Syncere Skin Systems, UCB, Verrica Pharmaceuticals, Yobee Care Inc.; Consultant: AbbVie, Amyris Inc, Burt’s Bees, Dermira, Eli Lilly, Exeltis, Franklin BioScience, Kiniksa Pharmaceuticals, Leo Pharma, L’Oréal, Odeza LLC, Theraplex, TopMD, Unilever; Research Investigator: AbbVie, AOBiome LLC, Regeneron; Speaker’s Bureau: La Roche-Posay, Pfizer, Pierre Fabre Dermatologie, Regeneron |
Scott McGee-Plys | NA |
Geoffrey C. Wall | Speaker Bureau: Janssen Pharmaceuticals and Tetraphase Pharmaceuticals. |
Lauren Welch | NA |
Ashley Whitehurst | NA |
How to Get Your Certificate
- Go to http://mlg.cmecertificateonline.com
- Click on “Using Managed Care to Minimize the Burden of Moderate-to-Severe Atopic Dermatitis in Pediatric and Adult Patients – Enduring” link.
- Complete the post-test, click the provided link to go to the online evaluation site.
- Evaluate the meeting, click the provided link to open your credit certificate.
- Print/save all pages of your certificate for your records.
Questions?
Email [email protected]
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.